Zacks Investment Research cut shares of Strongbridge Biopharma PLC (NASDAQ:SBBP) from a buy rating to a hold rating in a research report sent to investors on Wednesday.

According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “

Several other research firms have also recently weighed in on SBBP. ValuEngine cut Strongbridge Biopharma PLC from a hold rating to a sell rating in a research report on Monday, October 2nd. HC Wainwright reiterated a buy rating and set a $18.00 price objective on shares of Strongbridge Biopharma PLC in a research note on Wednesday, November 15th. Finally, Oppenheimer Holdings, Inc. began coverage on Strongbridge Biopharma PLC in a research note on Thursday, August 10th. They set an outperform rating and a $12.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of Hold and a consensus price target of $11.81.

Shares of Strongbridge Biopharma PLC (NASDAQ:SBBP) traded up $0.20 during trading hours on Wednesday, hitting $6.55. The company had a trading volume of 243,600 shares, compared to its average volume of 106,232. The company has a debt-to-equity ratio of -1.89, a quick ratio of 4.61 and a current ratio of 4.70. Strongbridge Biopharma PLC has a one year low of $2.00 and a one year high of $8.85.

TRADEMARK VIOLATION WARNING: This news story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/23/strongbridge-biopharma-plc-sbbp-lowered-to-hold-at-zacks-investment-research.html.

Hedge funds have recently modified their holdings of the stock. State of Wisconsin Investment Board bought a new stake in shares of Strongbridge Biopharma PLC in the 2nd quarter worth $114,000. Rhumbline Advisers acquired a new stake in Strongbridge Biopharma PLC in the 2nd quarter valued at about $154,000. California State Teachers Retirement System acquired a new stake in Strongbridge Biopharma PLC in the 2nd quarter valued at about $277,000. Teachers Advisors LLC acquired a new stake in Strongbridge Biopharma PLC in the 2nd quarter valued at about $297,000. Finally, Bank of New York Mellon Corp acquired a new stake in Strongbridge Biopharma PLC in the 2nd quarter valued at about $331,000. Institutional investors own 56.29% of the company’s stock.

About Strongbridge Biopharma PLC

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Receive News & Stock Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related stocks with our FREE daily email newsletter.